...
首页> 外文期刊>International journal of clinical pharmacology and therapeutics >Pain leads the way: the development of evidence-based medicine for pain relief
【24h】

Pain leads the way: the development of evidence-based medicine for pain relief

机译:止痛之道:开发基于证据的止痛药

获取原文
获取原文并翻译 | 示例

摘要

This paper describes the development of evidence based methods in pain medicine since the 1980s at the Pain Research Department of the Nuffield Department of Clinical Neurosciences, Oxford University. Pain medicine can be said to have led the way in terms of developing registers of randomized controlled trials (RCTs) and in developing appropriate methodology for assessing clinical trials and developing metanalytical techniques. This paper tells the story of that development which occurred in conjunction with the development of the Cochrane Collaboration. Pain has a larger body of evidence than many medical specialties with more than 30,000 RCTs and over 2,500 published systematic reviews. Our work continues to raise methodological challenges and a number of key ones are described: Size: We have added to the existing literature to show that small studies overestimate treatment effects. We consider studies with less than 50 participants per treatment group to be at high risk of bias. Mean pain scores: We have shown these to be unhelpful and misleading. We illustrate that response to analgesics is a U-shaped curve with a larger proportion of participants having either a poor response or a good response. Imputation: We discuss the problems of current methods. Tiers of evidence: We propose a way to assess evidence for pain studies. Duplicate publication of data can lead to inflated benefits in systematic reviews. In addition we touch on fraud, pharmaceutical company funding. The final sections cover developments in several areas of pain medicine, and suggest some developments going forward.
机译:本文介绍了自1980年代以来牛津大学纳菲尔德临床神经科学系疼痛研究系的基于证据的疼痛医学方法的发展。可以说,止痛药在开发随机对照试验(RCT)登记册以及开发评估临床试验和开发荟萃分析技术的适当方法方面一直处于领先地位。本文讲述了与Cochrane合作的发展同时发生的发展故事。与许多医学专科相比,疼痛具有更多的证据,拥有超过30,000个RCT和2500多个已发表的系统评价。我们的工作继续提出方法上的挑战,并描述了许多关键挑战:规模:我们已经添加到现有文献中来显示,小型研究高估了治疗效果。我们认为每个治疗组参与者少于50名的研究存在偏见的高风险。平均疼痛评分:我们显示这些评分无助且具有误导性。我们举例说明,对止痛药的反应是一条U形曲线,其中较大比例的参与者反应较差或反应良好。归因:我们讨论当前方法的问题。证据层:我们提出了一种评估疼痛研究证据的方法。重复发布数据可能导致系统评价的收益过高。此外,我们还涉及欺诈,制药公司的资金筹措。最后几节介绍了止痛药在多个领域的发展,并提出了未来的一些发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号